| 0 | 💬 0 |
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
(nature.com)
|
Nature Medicine 2026-04-20 | #immunotherapy #car-t #toxicity #myeloma #minimal residual disease |